PEPFAR's biggest success is also its largest liability
- 1 July 2009
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 374 (9685) , 184-185
- https://doi.org/10.1016/s0140-6736(09)61312-x
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic ReviewPLoS Medicine, 2007
- Rapid Scale-up of Antiretroviral Therapy at Primary Care Sites in ZambiaJAMA, 2006
- Antiretroviral Therapy in a Thousand Patients with AIDS in HaitiNew England Journal of Medicine, 2005
- Lessons Learned from Use of Highly Active Antiretroviral Therapy in AfricaClinical Infectious Diseases, 2005
- Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trialThe Lancet, 2004
- Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South AfricaAIDS, 2004
- Highly active antiretroviral therapy in resource-poor settingsAIDS, 2003
- Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistanceThe Lancet, 2002